Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It ‘Disappointing’
Ikena Oncology halts its IK-930 program after reviewing clinical data and resources, focusing on the novel MEK-RAF molecular glue, IK-595.
Turbulent Outlook For American Airlines: Analysts Cut Forecasts As Competitive Pressures Mount
American Airlines lowers Q2 EPS guidance, analysts cut price target. Departure of Chief Commercial Officer announced.
This American Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
With FDA Decision Date Approaching, Analyst Downgrades Sarepta On Balanced Risk And Reward
RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recent stock surge.
Under Armour’s Turnaround May Take Time; Investors Should Wait For ‘Clearer Signals,’ Says Analyst
Under Armour (UAA) reported revenue decline, received downgrade from JPMorgan. Analyst advises caution, company's restructuring plan may take time.
Aon Faces Challenges With Integration Risks And Slow Growth: BofA Downgrades Stock
BofA Securities analyst downgrades Aon plc to Underperform, citing underperformance, integration risk, and management changes. $306 price target.
Why Is Garmin Stock Falling Today?
Garmin stock downgraded to Underperform by B of A analyst due to concerns about growth momentum and valuation. Q1 results beat estimates.
This Walt Disney Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Today
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
Under Armour Is Lagging Behind Peers Like Nike & Lululemon! Analyst Explains Why
Under Armour faces challenges as it lags behind competitors, with analysts noting concerns over revenue decline, product innovation, and profitability.
Occidental Petroleum Could Offer ‘Minimal Shareholder Return’: Analyst
The Occidental/CrownRock acquisition is expected to close in the current quarter, and is likely to be less accretive than other recent deals.